Abeona Therapeutics (ABEO) Equity Average (2011 - 2026)

Abeona Therapeutics' Equity Average history runs 16 years deep, the most recent figure standing at $152.1 million for Q1 2026.

• In Q1 2026, Equity Average rose 256.04% year-over-year to $152.1 million; the TTM figure through Mar 2026 stood at $152.1 million (up 256.04% YoY), while the FY2025 annual figure was $101.6 million, up 245.32% from the prior year.
• Equity Average was $152.1 million for Q1 2026 at Abeona Therapeutics, down from $165.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $167.4 million in Q3 2025 to a low of $3.0 million in Q1 2024.
• Historically, Equity Average has averaged $54.3 million across 5 years, with a median of $31.8 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Equity Average sank 86.93% in 2024, then surged 1336.96% in 2025.
• A 5-year view of Equity Average shows it stood at $19.6 million in 2022, then decreased by 5.87% to $18.4 million in 2023, then surged by 143.61% to $44.9 million in 2024, then jumped by 267.97% to $165.2 million in 2025, then declined by 7.96% to $152.1 million in 2026.
• The last three Equity Average figures came in at $152.1 million (Q1 2026), $165.2 million (Q4 2025), and $167.4 million (Q3 2025), per Business Quant data.